A comparison of dabigatran and warfarin for stroke prevention in elderly Asian population with nonvalvular atrial fibrillation: An audit of current practice in Malaysia
- Author:
Yap Swee HIEN
1
;
Ng Yau PIAO
;
Roslan ASLANNIF
;
Kolanthaivelu JAYAKHANTAN
;
Koh Kok WEI
;
P’ng Hon SHEN
;
Boo Yang LIANG
;
Hoo Fan KEE
;
Yap Lok BIN.
Author Information
1. Department of Cardiology, National Heart Institute, Kuala Lumpur, Malaysia
- Publication Type:Original article
- Keywords:
Atrial fibrillation;
dabigatran;
warfarin;
stroke prevention;
bleeding events
- From:
The Medical Journal of Malaysia
2017;72(6):360-364
- CountryMalaysia
- Language:English
-
Abstract:
Introduction: Atrial fibrillation (AF) is the most commoncardiac arrhythmia with significant morbidity and mortalityin relation to thromboembolic stroke. Our study aimed toevaluate the safety and efficacy of dabigatran in strokeprevention in elderly patient with nonvalvular AF with regardto the risk of ischemic stroke and intracranial haemorrhage(ICH) in real-world setting.Methods: A retrospective cohort study of 200 patients ondabigatran and warfarin from January 2009 till September2016 was carried out. Data were collected for 100 patients ondabigatran and 100 patients on warfarin.Results: The mean follow-up period was 340.7±322.3 daysfor dabigatran group and 410.5±321.2 days for warfaringroup. The mean time in therapeutic range (TTR) was52±18.7%. The mean CHA2DS2 -VASc score for dabigatrangroup was 4.4±1.1 while 5.0±1.5 for warfarin group. None indabigatran group experienced ischemic stroke compared toone patient in warfarin group (p=0.316). There was onepatient in dabigatran group suffered from ICH compared tonone in warfarin group (p=0.316). Four patients in warfaringroup experienced minor bleeding, while none fromdabigatran group (p=0.043).Conclusion: Overall bleeding events were significantly lowerin dabigatran group compared to warfarin group. In thepresence of suboptimal TTR rates and inconveniences withwarfarin therapy, non-vitamin-K antagonist oralanticoagulants (NOAC) are the preferred agents for strokeprevention in elderly Asian patients for nonvalvula
